ArticleFrontiers in oncology2026
Multi-omics and experimental validation reveal ISG20L2 as a potential pro-oncogenic regulator in gastric cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer is a major malignancy with molecular heterogeneity and limited biomarkers for risk stratification and therapeutic guidance. Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2), a regulator of ribosome biogenesis, has been implicated in tumor progression, but its relevance in gastric cancer is poorly defined. This study aimed to characterize the potential pro-oncogenic and immune relevance of ISG20L2 in gastric cancer. Methods: Public multi-omics datasets and two single-cell RNA-sequencing cohorts were used to evaluate ISG20L2 expression and its associations with molecular features, tumor functional states, immune infiltration, and immunotherapy-related characteristics. Protein expression was validated in gastric cancer cell lines and nine paired clinical tissues, and functional effects of ISG20L2 knockdown were assessed in AGS and HGC-27 cells. Results: ISG20L2 was significantly upregulated in gastric cancer and inversely correlated with promoter methylation. Single-cell analysis showed predominant enrichment of ISG20L2 in exhausted CD8+ T cells. High ISG20L2 expression was closely associated with cell-cycle activity, immune infiltration, PD-L1 expression and predicted immunotherapy response. Experimentally, ISG20L2 protein was elevated in gastric cancer cell lines and tumor tissues. ISG20L2 knockdown markedly suppressed proliferation, clonogenicity, migration and invasion in both AGS and HGC-27 cells. Conclusion: ISG20L2 is aberrantly upregulated and associated with malignant biological features and immune-related characteristics in gastric cancer, supporting its potential role as a pro-oncogenic regulator and a candidate molecular indicator requiring further clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.